請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/85708
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林先和(Hsien-Ho Lin) | |
dc.contributor.author | Winston Lie | en |
dc.contributor.author | 賴思腾 | zh_TW |
dc.date.accessioned | 2023-03-19T23:22:05Z | - |
dc.date.copyright | 2022-06-21 | |
dc.date.issued | 2022 | |
dc.date.submitted | 2022-06-17 | |
dc.identifier.citation | 1. WHO. Tackling the drug-resistant TB crisis. (n.d.). Retrieved April 29, 2022, from https://www.who.int/activities/tackling-the-drug-resistant-tb-crisis 2. Blumberg, H. M., Burman, W. J., Chaisson, R. E., Daley, C. L., Etkind, S. C., Friedman, L. N., Fujiwara, P., Grzemska, M., Hopewell, P. C., Iseman, M. D., Jasmer, R. M., Koppaka, V., Menzies, R. I., O’Brien, R. J., Reves, R. R., Reichman, L. B., Simone, P. M., Starke, J. R., Vernon, A. A., & American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society. (2003). American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of tuberculosis. American Journal of Respiratory and Critical Care Medicine, 167(4), 603–662. https://doi.org/10.1164/rccm.167.4.603 3. WHO. Global tuberculosis report 2021. (n.d.). Retrieved April 28, 2022, from https://www.who.int/publications-detail-redirect/9789240037021 4. Seung, K. J., Keshavjee, S., & Rich, M. L. (2015). Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis. Cold Spring Harbor Perspectives in Medicine, 5(9), a017863. https://doi.org/10.1101/cshperspect.a017863 5. Dheda, K., Gumbo, T., Maartens, G., Dooley, K. E., Murray, M., Furin, J., Nardell, E. A., Warren, R. M., & Lancet Respiratory Medicine drug-resistant tuberculosis Commission group. (2019). The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. The Lancet. Respiratory Medicine, 7(9), 820–826. https://doi.org/10.1016/S2213-2600(19)30263-2 6. Horne, D. J., Pinto, L. M., Arentz, M., Lin, S.-Y. G., Desmond, E., Flores, L. L., Steingart, K. R., & Minion, J. (2013). Diagnostic Accuracy and Reproducibility of WHO-Endorsed Phenotypic Drug Susceptibility Testing Methods for First-Line and Second-Line Antituberculosis Drugs. Journal of Clinical Microbiology, 51(2), 393–401. https://doi.org/10.1128/JCM.02724-12 7. WHO.New diagnostic test and better treatment for multidrug-resistant tuberculosis. (n.d.). Retrieved April 26, 2022, from https://www.who.int/news/item/12-05-2016-rapid-diagnostic-test-and-shorter-cheaper-treatment-signal-new-hope-for-multidrug-resistant-tuberculosis-patients 8. WHO. WHO Endorses New Rapid Tuberculosis Test. (n.d.). Retrieved April 26, 2022, from https://www.who.int/news/item/08-12-2010-who-endorses-new-rapid-tuberculosis-test 9. Balasingham, S. V., Davidsen, T., Szpinda, I., Frye, S. A., & Tønjum, T. (2009). Molecular Diagnostics in Tuberculosis. Molecular Diagnosis & Therapy, 13(3), 137–151. https://doi.org/10.1007/BF03256322 10. García-Basteiro, A. L., DiNardo, A., Saavedra, B., Silva, D. R., Palmero, D., Gegia, M., Migliori, G. B., Duarte, R., Mambuque, E., Centis, R., Cuevas, L. E., Izco, S., & Theron, G. (2018). Point of care diagnostics for tuberculosis. Pulmonology, 24(2), 73–85. https://doi.org/10.1016/j.rppnen.2017.12.002 11. US CDC. General Considerations | Rapid Molecular Testing | Laboratory Info | TB | CDC. (2020, April 14). https://www.cdc.gov/tb/topic/laboratory/rapidmoleculartesting/considerations.htm 12. Cabibbe, A. M., Walker, T. M., Niemann, S., & Cirillo, D. M. (2018). Whole genome sequencing of Mycobacterium tuberculosis. European Respiratory Journal, 52(5). https://doi.org/10.1183/13993003.01163-2018 13. Van Deun, A., Aung, K. J. M., Bola, V., Lebeke, R., Hossain, M. A., de Rijk, W. B., Rigouts, L., Gumusboga, A., Torrea, G., & de Jong, B. C. (2013). Rifampin drug resistance tests for tuberculosis: Challenging the gold standard. Journal of Clinical Microbiology, 51(8), 2633–2640. https://doi.org/10.1128/JCM.00553-13 14. Cohen, K. A., Manson, A. L., Desjardins, C. A., Abeel, T., & Earl, A. M. (2019). Deciphering drug resistance in Mycobacterium tuberculosis using whole-genome sequencing: Progress, promise, and challenges. Genome Medicine, 11(1). https://doi.org/10.1186/s13073-019-0660-8 15. WHO (2021).Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance. (n.d.). Retrieved April 28, 2022, from https://www.who.int/publications-detail-redirect/9789240028173 16. Walker, T. M., Miotto, P., Köser, C. U., Fowler, P. W., Knaggs, J., Iqbal, Z., Hunt, M., Chindelevitch, L., Farhat, M., Cirillo, D. M., Comas, I., Posey, J., Omar, S. V., Peto, T. E., Suresh, A., Uplekar, S., Laurent, S., Colman, R. E., Nathanson, C.-M., … Rodwell, T. C. (2022). The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: A genotypic analysis. The Lancet. Microbe, 3(4), e265–e273. https://doi.org/10.1016/S2666-5247(21)00301-3 17. Schleusener, V., Köser, C. U., Beckert, P., Niemann, S., & Feuerriegel, S. (2017). Mycobacterium tuberculosis resistance prediction and lineage classification from genome sequencing: Comparison of automated analysis tools. Scientific Reports, 7(1), 46327. https://doi.org/10.1038/srep46327 18. van Beek, J., Haanperä, M., Smit, P. W., Mentula, S., & Soini, H. (2019). Evaluation of whole genome sequencing and software tools for drug susceptibility testing of Mycobacterium tuberculosis. Clinical Microbiology and Infection, 25(1), 82–86. https://doi.org/10.1016/j.cmi.2018.03.041 19. The CRyPTIC Consortium and the 100,000 Genomes Project. Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing. (2018). New England Journal of Medicine, 379(15), 1403–1415. https://doi.org/10.1056/NEJMoa1800474 20. Walker, T. M., Kohl, T. A., Omar, S. V., Hedge, J., Del Ojo Elias, C., Bradley, P., Iqbal, Z., Feuerriegel, S., Niehaus, K. E., Wilson, D. J., Clifton, D. A., Kapatai, G., Ip, C. L. C., Bowden, R., Drobniewski, F. A., Allix-Béguec, C., Gaudin, C., Parkhill, J., Diel, R., … Peto, T. E. A. (2015). Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: A retrospective cohort study. The Lancet. Infectious Diseases, 15(10), 1193–1202. https://doi.org/10.1016/S1473-3099(15)00062-6 21. Köser, C. U., Bryant, J. M., Becq, J., Török, M. E., Ellington, M. J., Marti-Renom, M. A., Carmichael, A. J., Parkhill, J., Smith, G. P., & Peacock, S. J. (2013). Whole-Genome Sequencing for Rapid Susceptibility Testing of M. tuberculosis. New England Journal of Medicine, 369(3), 290–292. https://doi.org/10.1056/NEJMc1215305 22. Pankhurst, L. J., Elias, C. del O., Votintseva, A. A., Walker, T. M., Cole, K., Davies, J., Fermont, J. M., Gascoyne-Binzi, D. M., Kohl, T. A., Kong, C., Lemaitre, N., Niemann, S., Paul, J., Rogers, T. R., Roycroft, E., Smith, E. G., Supply, P., Tang, P., Wilcox, M. H., … Crook, D. W. (2016). Rapid, comprehensive, and affordable mycobacterial diagnosis with whole-genome sequencing: A prospective study. The Lancet Respiratory Medicine, 4(1), 49–58. https://doi.org/10.1016/S2213-2600(15)00466-X 23. Wu, X., Tan, G., Sha, W., Liu, H., Yang, J., Guo, Y., Shen, X., Wu, Z., Shen, H., & Yu, F. (n.d.). Use of Whole-Genome Sequencing to Predict Mycobacterium tuberculosis Complex Drug Resistance from Early Positive Liquid Cultures. Microbiology Spectrum, 10(2), e02516-21. https://doi.org/10.1128/spectrum.02516-21 24. Sánchez-Corrales, L., Tovar-Aguirre, O. L., Galeano-Vanegas, N. F., Jiménez, P. A. C., Martínez-Vega, R. A., Maldonado-Londoño, C. E., Hernández-Botero, J. S., & Siller-López, F. (2021). Phylogenomic analysis and Mycobacterium tuberculosis antibiotic resistance prediction by whole-genome sequencing from clinical isolates of Caldas, Colombia. PLOS ONE, 16(10), e0258402. https://doi.org/10.1371/journal.pone.0258402 25. Xie, Y. L., Chakravorty, S., Armstrong, D. T., Hall, S. L., Via, L. E., Song, T., Yuan, X., Mo, X., Zhu, H., Xu, P., Gao, Q., Lee, M., Lee, J., Smith, L. E., Chen, R. Y., Joh, J. S., Cho, Y., Liu, X., Ruan, X., … Alland, D. (2017). Evaluation of a Rapid Molecular Drug-Susceptibility Test for Tuberculosis. The New England Journal of Medicine, 377(11), 1043–1054. https://doi.org/10.1056/NEJMoa1614915 26. Liu, D., Huang, F., Zhang, G., He, W., Ou, X., He, P., Zhao, B., Zhu, B., Liu, F., Li, Z., Liu, C., Xia, H., Wang, S., Zhou, Y., Walker, T. M., Liu, L., Crook, D. W., & Zhao, Y. (2021). Whole-genome sequencing for surveillance of tuberculosis drug resistance and determination of resistance level in China. Clinical Microbiology and Infection, 0(0). https://doi.org/10.1016/j.cmi.2021.09.014 27. Yu, M.-C., Hung, C.-S., Huang, C.-K., Wang, C.-H., Liang, Y.-C., & Lin, J.-C. (2021). Integrative utility of long read sequencing-based whole genome analysis and phenotypic assay on differentiating isoniazid-resistant signature of Mycobacterium tuberculosis. Journal of Biomedical Science, 28(1), 86. https://doi.org/10.1186/s12929-021-00783-x 28. Clinical Microbiology Procedures Handbook, Volumes 1-3 (3rd Edition). (n.d.). Retrieved May 9, 2022, from https://app.knovel.com/kn/resources/kpCMPHVE03/toc 29. Taiwan CDC. Guidelines and Materials on Tuberculosis Testing (n.d.). Retrieved May 9, 2022, from https://www.cdc.gov.tw/Category/MPage/YpPM4PxFx3b_6FKuMDYjew 30. Larsen, M. H., Biermann, K., Tandberg, S., Hsu, T., & Jacobs, W. R. (2007). Genetic Manipulation of Mycobacterium tuberculosis. Current Protocols in Microbiology, Chapter 10, Unit 10A.2. https://doi.org/10.1002/9780471729259.mc10a02s6 31. Coll, F., McNerney, R., Preston, M. D., Guerra-Assunção, J. A., Warry, A., Hill-Cawthorne, G., Mallard, K., Nair, M., Miranda, A., Alves, A., Perdigão, J., Viveiros, M., Portugal, I., Hasan, Z., Hasan, R., Glynn, J. R., Martin, N., Pain, A., & Clark, T. G. (2015). Rapid determination of anti-tuberculosis drug resistance from whole-genome sequences. Genome Medicine, 7(1), 51. https://doi.org/10.1186/s13073-015-0164-0 32. Phelan, J. E., O’Sullivan, D. M., Machado, D., Ramos, J., Oppong, Y. E. A., Campino, S., O’Grady, J., McNerney, R., Hibberd, M. L., Viveiros, M., Huggett, J. F., & Clark, T. G. (2019). Integrating informatics tools and portable sequencing technology for rapid detection of resistance to anti-tuberculous drugs. Genome Medicine, 11(1), 41. https://doi.org/10.1186/s13073-019-0650-x 33. Napier, G., Campino, S., Merid, Y., Abebe, M., Woldeamanuel, Y., Aseffa, A., Hibberd, M. L., Phelan, J., & Clark, T. G. (2020). Robust barcoding and identification of Mycobacterium tuberculosis lineages for epidemiological and clinical studies. Genome Medicine, 12(1), 114. https://doi.org/10.1186/s13073-020-00817-3 34. Seifert, M., Catanzaro, D., Catanzaro, A., & Rodwell, T. C. (2015). Genetic Mutations Associated with Isoniazid Resistance in Mycobacterium tuberculosis: A Systematic Review. PLoS ONE, 10(3), e0119628. https://doi.org/10.1371/journal.pone.0119628 35. Zaczek, A., Brzostek, A., Augustynowicz-Kopec, E., Zwolska, Z., & Dziadek, J. (2009). Genetic evaluation of relationship between mutations in rpoB and resistance of Mycobacterium tuberculosis to rifampin. BMC Microbiology, 9, 10. https://doi.org/10.1186/1471-2180-9-10 36. Ford, C. B., Lin, P. L., Chase, M. R., Shah, R. R., Iartchouk, O., Galagan, J., Mohaideen, N., Ioerger, T. R., Sacchettini, J. C., Lipsitch, M., Flynn, J. L., & Fortune, S. M. (2011). Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. Nature Genetics, 43(5), 482–486. https://doi.org/10.1038/ng.811 37. Ford, C. B., Shah, R. R., Maeda, M. K., Gagneux, S., Murray, M. B., Cohen, T., Johnston, J. C., Gardy, J., Lipsitch, M., & Fortune, S. M. (2013). Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis. Nature Genetics, 45(7), 784–790. https://doi.org/10.1038/ng.2656 38. Zuur, M. A., Pasipanodya, J. G., van Soolingen, D., van der Werf, T. S., Gumbo, T., & Alffenaar, J.-W. C. (2018). Intermediate Susceptibility Dose-Dependent Breakpoints For High-Dose Rifampin, Isoniazid, and Pyrazinamide Treatment in Multidrug-Resistant Tuberculosis Programs. Clinical Infectious Diseases, 67(11), 1743–1749. https://doi.org/10.1093/cid/ciy346 39. Hsueh, P.-R., Liu, Y.-C., So, J., Liu, C.-Y., Yang, P.-C., & Luh, K.-T. (2006). Mycobacterium tuberculosis in Taiwan. Journal of Infection, 52(2), 77–85. https://doi.org/10.1016/j.jinf.2005.08.008 40. Lee, P.-H., Chan, P.-C., Peng, Y.-T., Chu, P.-W., Wu, M.-H., Jou, R., Yu, M.-C., Lin, C.-J., Huang, Y.-W., Chien, S.-T., Lee, J.-J., & Chiang, C.-Y. (2019). Impact of universal drug susceptibility testing and effective management of multidrug-resistant tuberculosis in Taiwan. PLOS ONE, 14(4), e0214792. https://doi.org/10.1371/journal.pone.0214792 41. Wu, S.-H., Chan, H.-H., Hsiao, H.-C., & Jou, R. (2021). Primary Bedaquiline Resistance Among Cases of Drug-Resistant Tuberculosis in Taiwan. Frontiers in Microbiology, 12, 754249. https://doi.org/10.3389/fmicb.2021.754249 42. Narmandakh, E., Tumenbayar, O., Borolzoi, T., Erkhembayar, B., Boldoo, T., Dambaa, N., Burneebaatar, B., Nymadawa, N., Mitarai, S., Jav, S., & Chiang, C.-Y. (2020). Genetic Mutations Associated with Isoniazid Resistance in Mycobacterium tuberculosis in Mongolia. Antimicrobial Agents and Chemotherapy, 64(7), e00537-20. https://doi.org/10.1128/AAC.00537-20 43. Monroe, J. G., Srikant, T., Carbonell-Bejerano, P., Becker, C., Lensink, M., Exposito Alonso, M., Klein, M., Hildebrandt, J., Neumann, M., Kliebenstein, D., Weng, M.-L., Imbert, E., Ågren, J., Rutter, M. T., Fenster, C. B., & Weigel, D. (2022). Mutation bias reflects natural selection in Arabidopsis thaliana. Nature, 602(7895), 101–105. https://doi.org/10.1038/s41586-021-04269-6 44. Zhang, J. (2022). Important genomic regions mutate less often than do other regions. Nature, 602(7895), 38–39. https://doi.org/10.1038/d41586-022-00017-6 45. Knight, G. M., Colijn, C., Shrestha, S., Fofana, M., Cobelens, F., White, R. G., Dowdy, D. W., & Cohen, T. (2015). The Distribution of Fitness Costs of Resistance-Conferring Mutations Is a Key Determinant for the Future Burden of Drug-Resistant Tuberculosis: A Model-Based Analysis. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 61(Suppl 3), S147–S154. https://doi.org/10.1093/cid/civ579 46. Niehaus, A. J., Mlisana, K., Gandhi, N. R., Mathema, B., & Brust, J. C. M. (2015). High Prevalence of inhA Promoter Mutations among Patients with Drug-Resistant Tuberculosis in KwaZulu-Natal, South Africa. PLOS ONE, 10(9), e0135003. https://doi.org/10.1371/journal.pone.0135003 47. Hsu, L.-Y., Lai, L.-Y., Hsieh, P.-F., Lin, T.-L., Lin, W.-H., Tasi, H.-Y., Lee, W.-T., Jou, R., & Wang, J.-T. (2020). Two Novel katG Mutations Conferring Isoniazid Resistance in Mycobacterium tuberculosis. Frontiers in Microbiology, 11. https://www.frontiersin.org/article/10.3389/fmicb.2020.01644 48. Taiwan CDC. Tuberculosis Whole Genome Detection Technology Applied in Tuberculosis Surveillance Research Report pdf. (n.d.). Retrieved June 5, 2022, from https://www.cdc.gov.tw/File/Get/sqrAKrJg_Uq8Ki5B0HtO3g?name=joROxZZFvUHQ0af0BXzJuibbCAppPwQe_WBdO4M_BRM&path=NpAMXiIxls6Ls4XFgIQG9cvhz6v3yO-edxp9SnKlLh24aI84mmVfdjMPIFNZRr37 49. Taiwan CDC. Taiwan Guidelines for TB Diagnosis & Treatment (6E). (n.d.). Retrieved April 28, 2022, from https://www.cdc.gov.tw/En/InfectionReport/Info/9YUAXbFsmorP5T10V8qvMA?infoId=_4WqQoF5dXs4xvRcCJbkMw 50. Witney, A. A., Gould, K. A., Arnold, A., Coleman, D., Delgado, R., Dhillon, J., Pond, M. J., Pope, C. F., Planche, T. D., Stoker, N. G., Cosgrove, C. A., Butcher, P. D., Harrison, T. S., & Hinds, J. (2015). Clinical application of whole-genome sequencing to inform treatment for multidrug-resistant tuberculosis cases. Journal of Clinical Microbiology, 53(5), 1473–1483. https://doi.org/10.1128/JCM.02993-14 | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/85708 | - |
dc.description.abstract | 結核病是其中一個導致死亡的主要傳染病之一,且抗藥性菌株的傳播使問題更惡化,改善抗藥性結核病的診斷將能成功幫助全球結核病的預防與治療。此研究以培養為主的藥敏性測試為基準來評估全基因定序診斷到的表現。我們分析來自台灣高雄市於2019年1月至2021年7月之結核菌培養陽性通報個案中超過85%,將近2000隻TB菌株,發現全基因定序能達到接近90%的敏感性及高於95%的特異性及診斷正確率。我們也使用全基因定序來預測多種結核病藥物之盛行率,發現與傳統藥敏性測試之表現型結果有很高的一致性。整體而言,研究結果提供使用全基因定序診斷抗藥性結核病以及未來如何將其應用於臨床和公共衛生中的重要支持。 | zh_TW |
dc.description.abstract | Tuberculosis (TB) is one of the largest contributors to mortality among all communicable diseases, and the spread of drug-resistant strains will only exacerbate this problem. Diagnostic methods in detecting drug-resistant tuberculosis (DR-TB) need to improve if global prevention and treatment efforts are to be successful. In this study, we evaluate the performance of whole genome sequencing (WGS) in detecting DR-TB compared to culture-based, drug susceptibility testing (DST). To do this, we prospectively analyzed nearly 2,000 TB isolates from Kaohsiung, Taiwan, between January 2019 to July 2021 and achieved a coverage rate of 85% for all TB cases in the city. We found sensitivity as high as 90% for certain anti-TB drugs and greater than 95% for specificity and diagnostic accuracy. Additionally, we used WGS to predict the resistance prevalence for various drugs and found great agreement with what was determined by phenotypic DST. Overall, our results provide greater support on the use of WGS in diagnosing DR-TB, and how it may be applied in both clinical and public health settings. | en |
dc.description.provenance | Made available in DSpace on 2023-03-19T23:22:05Z (GMT). No. of bitstreams: 1 U0001-1306202200121500.pdf: 1694248 bytes, checksum: e581f663caff4f0c51ec54419a1a29d5 (MD5) Previous issue date: 2022 | en |
dc.description.tableofcontents | Certificate of Thesis Approval.…………………………………………………………...i Abstract (Chinese Version)…..…………………...………………………………...…..ii Abstract (English Version)…………………………….…………………………….…...iii List of Tables and Figures……………………………………………….………….……...v Introduction………………………………….…………………………………………............1 Methods…………………….……………………………………………….....……….......……3 Results……………………………………………………………………………............……....6 Discussion………………………………………………………………………………...........20 References…………………………...……………………………………..........……………29 | |
dc.language.iso | en | |
dc.title | 利用全基因定序預測結核病之抗藥性 | zh_TW |
dc.title | Predicting Drug Resistance in Mycobacterium Tuberculosis Using Whole Genome Sequencing | en |
dc.type | Thesis | |
dc.date.schoolyear | 110-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 廖俊星(Chun-Hsing Liao),江振源(Chen-Yuan Chiang) | |
dc.subject.keyword | 結核病,全基因定序,藥物敏感性測試, | zh_TW |
dc.subject.keyword | tuberculosis,whole genome sequencing,phenotypic drug susceptibility testing, | en |
dc.relation.page | 38 | |
dc.identifier.doi | 10.6342/NTU202200927 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2022-06-17 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 全球衛生碩士/博士學位學程 | zh_TW |
dc.date.embargo-lift | 2022-06-21 | - |
顯示於系所單位: | 全球衛生學位學程 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
U0001-1306202200121500.pdf | 1.65 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。